Kyle Greenway
Assistant Professor in Psychiatry at McGill University; attending psychiatrist at the Jewish General Hospital; investigator at the Lady Davis Institute
Data updated
Research Footprint
Kyle Greenway appears in 10 tracked papers (2020–2026) and 1 clinical trial, most studied alongside Psilocybin, Ketamine and MDMA, across Depressive Disorders, Anxiety Disorders and PTSD.
Most-cited paper: Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments (85 citations).
Frequent co-authors: Robin Carhart-Harris, David Erritzoe and Brandon Weiss.
Publication Landscape
How the 10 papers Blossom tracks for Kyle Greenway line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of August 2026, not a complete bibliography.
How has Kyle Greenway's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 10 of 10 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Kyle Greenway publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Kyle Greenway publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Kyle T. Greenway, MD, MSc, FRCPC, is an Assistant Professor in Psychiatry at McGill University, a staff psychiatrist at the Jewish General Hospital, and an investigator at the Lady Davis Institute. His research focuses on novel psychiatric interventions, especially psychedelic-assisted psychotherapies, ketamine-assisted therapy, and the role of extra-pharmacological factors such as set and setting in treatment outcomes. He also directs the Jewish General Hospital’s ketamine-assisted therapy program and has trained at Imperial College’s Psychedelic Research Centre.
Key Impact
He is a McGill-based psychiatrist and psychedelic researcher who co-led the ReSPCT guidelines for psychedelic clinical trials and studies ketamine- and psilocybin-assisted therapies.
Collaboration Network
25 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Kyle Greenway's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Kyle Greenway is associated with.
McGill University
A leading Canadian research university in Montreal, Quebec, McGill pioneered the “Montreal Model”—an integrative biomedical-psychedelic approach to ketamine-assisted psychotherapy for severe treatment-resistant depression developed over 6 years and 500+ ketamine treatments. The team’s MUSIK randomized trial demonstrated that emotional and mystical ketamine experiences within a structured therapeutic environment drive more sustained antidepressant improvements, including in ketamine vs. ECT comparison trials.
View stakeholder →Imperial College London
academicThe Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →